{"nctId":"NCT01191255","briefTitle":"A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis","startDateStruct":{"date":"2010-10"},"conditions":["Hyperphosphatemia","Kidney Failure"],"count":441,"armGroups":[{"label":"Active Control","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo"]},{"label":"KRX-0502 (Ferric Citrate)","type":"EXPERIMENTAL","interventionNames":["Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo"]}],"interventions":[{"name":"ferric citrate, ca acetate, sevelamer carbonate, placebo","otherNames":["PhosLo","Renvela","KRX-0502","Zerenex"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Males or non-pregnant, non-breast-feeding females\n2. Age ≥18 years\n3. On thrice-weekly hemodialysis or on peritoneal dialysis for at least the previous three months prior to Screening\n4. Serum phosphorus ≥6.0 mg/dL for study entry\n5. Taking less than 3-18 pills/day of current phosphate binder\n6. Willing to be discontinued from current phosphate binder(s) and initiated on ferric citrate\n7. Willing and able to give informed consent\n8. Life expectancy \\>1 year\n\nExclusion Criteria:\n\n1. Parathyroidectomy within six months prior to Screening\n2. Actively symptomatic gastrointestinal bleeding or inflammatory bowel disease\n3. History of multiple drug allergies or intolerances\n4. History of malignancy in the last five years (treated cervical or non-melanomatous skin cancer may be permitted if approved by CCC)\n5. Previous intolerance to oral ferric citrate\n6. Intolerance to oral iron-containing products\n7. Psychiatric disorder that interferes with the patient's ability to comply with the study protocol\n8. Inability to tolerate oral drug intake\n9. Intolerance to calcium acetate and sevelamer carbonate\n10. Any other medical condition that renders the patient unable to or unlikely to complete the trial or that would interfere with optimal participation in the trial or produce significant risk to the patient\n11. Receipt of any investigational drug within 30 days of Screening Visit (Visit 0)\n12. Inability to cooperate with study personnel or history of noncompliance\n13. Unsuitable for this trial per Investigator's clinical judgment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Mean Serum Phosphorus From Baseline (Week 52) to the End of the Efficacy Assessment Period (EAP; Week 56)","description":"Patients who completed the 52-week Safety Assessment Period (SAP) on KRX-0502 (ferric citrate) were randomized in a 1:1 ratio to receive either KRX-0502 (ferric citrate) or Placebo for 4 weeks.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"5.44","spread":"1.459"},{"groupId":"OG003","value":"5.12","spread":"1.189"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"7.23","spread":"1.784"},{"groupId":"OG003","value":"4.89","spread":"1.291"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Serum Ferritin From Baseline to Week 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"609.50","spread":"307.689"},{"groupId":"OG001","value":"592.80","spread":"292.863"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"631.87","spread":"368.919"},{"groupId":"OG001","value":"894.88","spread":"481.788"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Serum Transferrin Saturation (TSAT) From Baseline to the End of the Safety Assessment Period (Week 52)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","spread":"11.57"},{"groupId":"OG001","value":"31.3","spread":"11.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.7","spread":"11.43"},{"groupId":"OG001","value":"39.2","spread":"16.78"}]}]}]},{"type":"SECONDARY","title":"IV Iron Analysis","description":"Full Analysis Population, cumulative IV Iron administration from Baseline to the end of the Safety Assessment Period (Week 52)","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.83","spread":null},{"groupId":"OG001","value":"1.87","spread":null}]}]}]},{"type":"SECONDARY","title":"ESA Analysis","description":"Full analysis population, cumulative Erythropoiesis-stimulating agent (ESA) administration from baseline to the end of the Safety Assessment Period (Week 52)","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"993.46","spread":null},{"groupId":"OG001","value":"755.80","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":114,"n":289},"commonTop":["Diarrhea","Nausea","Feces discolored","Vomiting","Vascular access complication"]}}}